Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average - Here's What Happened

Key Points

• Vaxart's stock price has fallen below its 200-day moving average of $0.40, trading as low as $0.33 before closing at $0.36.
• Several institutional investors have increased their stakes in Vaxart, with Jones Financial Companies growing its holdings by 276,364.7% recently.
• Vaxart is in the clinical-stage biotechnology sector, developing vaccines for norovirus, coronavirus, and seasonal influenza, along with a therapeutic vaccine for HPV.

Vaxart, Inc. (NASDAQ:VXRT - )'s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.40 and traded as low as $0.33. Vaxart shares last traded at $0.36, with a volume of 545,164 shares traded.

Vaxart Trading Up 1.7%

The firm's fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.40. The stock has a market capitalization of $81.27 million, a PE ratio of -1.31 and a beta of 1.39.

Institutional Investors Weigh In On Vaxart

Several hedge funds have recently modified their holdings of VXRT. Invesco Ltd. grew its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 70,568 shares during the period. Virtu Financial LLC acquired a new stake in Vaxart in the first quarter valued at approximately $56,000. Jones Financial Companies Lllp grew its holdings in Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after purchasing an additional 478,111 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Vaxart in the first quarter valued at approximately $31,000. Finally, Creative Planning acquired a new position in shares of Vaxart during the 2nd quarter worth approximately $33,000. 18.05% of the stock is owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.